Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2021-09-27 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
$12.1M R&D Tax Refund, Overseas Finding Increased to $139M 2 pages 201.9KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Telix Pharmaceuticals Limited regarding a $12.1M R&D tax refund and an expansion of an overseas R&D tax finding. It discusses government tax credits and funding related to R&D activities but does not contain any financial statements, quarterly or annual results, or detailed financial data. The document is relatively short (4198 characters) and reads as a corporate update or announcement rather than a formal financial report. There is no indication that this is an earnings release, annual report, or interim report. It is also not a regulatory certification or officer attestation. The content focuses on financing-related updates about tax credits and funding approvals, which aligns best with a Capital/Financing Update (CAP).
2021-09-27 English
FDA Extends New Drug Application Review Period for Illuccix 2 pages 211.2KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Telix Pharmaceuticals Limited regarding the FDA's extension of the New Drug Application (NDA) review period for their product Illuccix. It discusses regulatory review timelines, FDA meetings, and manufacturing observations but does not contain any financial data, earnings, or detailed report content. The document is relatively short (4601 characters) and serves as a regulatory update on the drug approval process rather than a financial or management report. It is not a full annual or interim report, earnings release, or investor presentation. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about the FDA review extension and related information.
2021-09-22 English
Telix Supporting Amgen PSMA-Targeting Therapy Trial 2 pages 199.4KB
Regulatory Filings Classification · 95% confidence The document is a company announcement about Telix Pharmaceuticals supplying a product to support a clinical trial by Amgen. It discusses a supply agreement, product development status, regulatory filings, and company background. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (3672 characters) and reads like a press release or corporate announcement rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a voting result, management change, or legal proceeding. The content is primarily about a business collaboration and product development update. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2021-09-14 English
FDA Approves Phase II Kidney Cancer Therapy Study 2 pages 169.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the FDA acceptance of an Investigational New Drug Application (IND) for a Phase II clinical study of a kidney cancer therapy by Telix Pharmaceuticals. It provides details about the study design, the investigational drug, and company background. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is an announcement of a clinical trial approval and related corporate information, not a financial report, management change, or shareholder meeting material. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial compliance. The content is primarily a corporate announcement about a clinical trial approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-09-13 English
NCCN Guidelines updated to include PSMA-PET Imaging 2 pages 205.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the National Comprehensive Cancer Network (NCCN) Guidelines have been updated to include PSMA PET imaging, specifically mentioning Telix Pharmaceuticals' investigational product Illuccix. It discusses regulatory statuses, clinical implications, and marketing authorisation progress but does not contain financial data, detailed financial results, or comprehensive report content. The document is an announcement of a guideline update and company product status rather than a financial report, regulatory filing, or management discussion. It is not a report publication announcement since it does not mention the release of a formal report but rather a guideline update and company news. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2021-09-13 English
Telix and Radius sign Distribution Agreement for Italy 2 pages 210.9KB
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a commercial distribution agreement between Telix Pharmaceuticals and Radius for a prostate cancer imaging product in Italy. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational reports. It is a corporate announcement about a business partnership and market expansion. The document length is 6128 characters, which is sufficient for a detailed announcement but does not contain financial or regulatory report content. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Capital/Financing Update (CAP) because it relates to a commercial agreement impacting the company's business operations and market presence, which is typical for CAP filings.
2021-09-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.